Abstract:Bevacizumab is one of the most common monoclonal antibodies used to treat cancer due to its antiangiogenic role. However, the frequent parenteral administrations are not attractive for the patient adhesion to the therapy. Nanoencapsulation of bevacizumab might be a useful alternative to increase administration intervals, due to controlled release properties. To achieve a long-term bevacizumab stability into PLGA nanoparticles, we developed an optimized and validated lyophilization protocol. The co-encapsulation of trehalose and bevacizumab into PLGA nanoparticles, associated to their lyophilization with external 10% (w/v) of trehalose, allowed maintenance of the physical-chemical characteristics of nanoparticles and bevacizumab secondary and tertiary structure. More relevant, the antiangiogenic activity of bevacizumab was kept over 6 months of storage while formulated with this protocol. No significant differences were found upon 6 months of storage at 4 °C and 25 °C/60% HR, and minor differences were observed for storage at 40 °C/75% HR, bringing to our knowledge, the first successfully report for monoclonal antibody storage at room temperature, without losing its structural and functional features. Our results served as starting point to understand the monoclonal antibody-based nanoparticle behavior over time, creating an innovative approach for a long-term monoclonal antibody stability. Statement of significance: Nanoencapsulation of monoclonal antibodies has boost the interest of researchers as an alternative to the current antibody-based therapy, changing the route of administrations through controlled release of monoclonal antibodies. Despite good results have been achieved with nanoencapsulation process, no strategy has still found concerning a long-term stability of nanoparticles and monoclonal antibodies. In this study, the aim was to find out a validated and optimized method that allows a long-term stability of nanoparticles and antibodies. Over 6 months of storage, an optimized nanosystem was considered stable for both nanoparticles and antibody structure, at 4 °C and 25 °C, resulting the first successfully report for monoclonal antibody storage at room temperature.

Effect of Nanoencapsulation Using Poly (Lactide-Co-glycolide) (PLGA) on Anti-Angiogenic Activity of Bevacizumab for Ocular Angiogenesis Therapy.

Mesoporous Silica Nanoparticles As a Delivery System for Improving Antiangiogenic Therapy

Enhanced Ocular Delivery of Beva via Ultra‐Small Polymeric Micelles for Noninvasive Anti‐VEGF Therapy

A comparison between the effects of two liposome-encapsulated bevacizumab formulations on ocular neovascularization inhibition

Effect Of Intravitreal Injection Of Bevacizumab-Chitosan Nanoparticles On Retina Of Diabetic Rats

Carbon nanostructures as a new high-performance platform for MR molecular imaging.

Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects

Targeted Long-term Noninvasive Treatment of Choroidal Neovascularization by Biodegradable Nanoparticles

Nanoparticles provide long-term stability of bevacizumab preserving its antiangiogenic activity

In Vitro Physicochemical and Pharmacokinetic Properties of Bevacizumab Dissolved in Silicone Oils Compared to Hydrogel-Substitutes and Porcine Vitreous Bodies

A Synergistic Therapy with Antioxidant and Anti‐VEGF: Towards Its Safe and Effective Elimination for Corneal Neovascularization

An injectable thermosensitive hydrogel for dual delivery of diclofenac and Avastin® to effectively suppress inflammatory corneal neovascularization

Inhibiting Corneal Neovascularization by Sustainably Releasing Anti-Vegf and Anti-Inflammation Drugs from Silica-Thermogel Nanohybrids

Combination therapy of cRGD-DOX self-assembled nanoparticles and bevacizumab for breast cancer

Cyclic RGD Peptide Targeting Coated Nano Drug Co-Delivery System for Therapeutic Use in Age-Related Macular Degeneration Disease

Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats: Bevacizumab a retinal anti-angiogenesis

Experimental Study on the Inhibitory Effect of Bevacizumab on Choroidal Neovascularization in Rat

Regional differences in the fine structure of the ciliary epithelium related to accommodation.

A peptidic network antibody inhibits both angiogenesis and inflammatory response

Developing a synergistic rate-retarding polymeric implant for controlling monoclonal antibody delivery in minimally invasive glaucoma surgery

An antibody-like peptidic network for anti-angiogenesis